News coverage about Arbutus Biopharma Corporation (NASDAQ:ABUS) has been trending somewhat positive on Friday, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Arbutus Biopharma Corporation earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.1414710482665 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern Sentiment’s analysis:
- Arbutus Biopharma Corporation (ABUS) Stock Unusual Activity – Wall Street Morning (wallstreetmorning.com)
- Company Spotlight: Arbutus Biopharma – Nasdaq (nasdaq.com)
- Arbutus Biopharma Corp (ABUS) Share Activity Climbing in Session – MTNV (mtnvnews.com)
- Alexion to Restructure Operations, to Lower Headcount by 20% – Nasdaq (nasdaq.com)
Arbutus Biopharma Corporation (ABUS) traded up 5.26% on Friday, reaching $5.00. The company’s stock had a trading volume of 354,989 shares. The firm’s 50 day moving average price is $3.96 and its 200-day moving average price is $3.53. Arbutus Biopharma Corporation has a 1-year low of $2.35 and a 1-year high of $5.05. The company’s market capitalization is $275.13 million.
A number of equities research analysts have recently commented on ABUS shares. Ladenburg Thalmann Financial Services started coverage on Arbutus Biopharma Corporation in a research note on Friday, June 2nd. They issued a “buy” rating and a $32.00 target price on the stock. Chardan Capital reissued a “buy” rating on shares of Arbutus Biopharma Corporation in a research note on Monday, August 7th. Finally, Zacks Investment Research raised Arbutus Biopharma Corporation from a “sell” rating to a “hold” rating in a report on Monday, July 10th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $12.81.
COPYRIGHT VIOLATION NOTICE: This report was posted by BBNS and is the sole property of of BBNS. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://baseballnewssource.com/markets/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-arbutus-biopharma-corporation-abus-stock-price/1566692.html.
In other Arbutus Biopharma Corporation news, insider Michael J. Sofia sold 30,000 shares of the firm’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $3.70, for a total value of $111,000.00. Following the sale, the insider now directly owns 1,563,403 shares in the company, valued at $5,784,591.10. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 10.00% of the stock is owned by company insiders.
About Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Receive News & Ratings for Arbutus Biopharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corporation and related companies with our FREE daily email newsletter.